article
Tweaking synonymous sites for gene therapy and vaccines
Professor Laurence D Hurst explains why understanding the nucleotide mutations in viruses, including SARS-CoV-2, can have significant implications for vaccine design.
List view / Grid view
Vaccine development
news
SARS-CoV-2 mutations do not increase transmissibility, research shows
Having analysed the SARS-CoV-2 genomes from over 46,723 patients, researchers have found no mutations that increase transmissibility.
news
COVID-19 vaccine tablet significantly reduces viral load in hamsters
Hamster challenge study results suggests the oral COVID-19 vaccine induces a robust immune response, protecting the animals from infection.
news
Study reveals roles of antibodies in SARS-CoV-2 disease severity
Researchers have found that the level of antibodies in the serum of SARS-CoV-2 patients correlated with disease severity.
news
COVID-19 vaccines should not be affected by SARS-CoV-2 mutations, researchers say
A common SARS-CoV-2 mutation known as D614G should not impact on the efficacy of COVID-19 vaccines, a study has shown.
news
Team identifies T-cell epitopes to inform COVID-19 vaccine development
Researchers studied 180 convalescent COVID-19 patients to reveal T-cell epitopes that they say can be targeted by a vaccine.
news
Bioengineered vaccine shows efficacy at protecting mice from COVID-19
Researchers have developed a novel vaccine using nucleotide untranslated regions that successfully protected mice from COVID-19.
news
Genetic analysis of SARS-CoV-2 reveals one vaccine could combat all infections
A genetic analysis of SARS-CoV-2 sequences reveal the virus has mutated minimally since December 2019, suggesting only one vaccine is needed to combat COVID-19.
news
Tracking SARS-CoV-2 evolution: notable mutations and potential targets
Researchers report that while the spike protein and RNA polymerase proteins have stabilised, other regions of the SARS-CoV-2 genome are becoming increasingly variable.
news
COVID-19 vaccine elicits high levels of neutralising antibodies in mice
A potential COVID-19 vaccine, made from a modified vesicular stomatitis virus with the SARS-CoV-2 Spike protein, was shown to protect mice against the virus.
news
Potential COVID-19 treatment and vaccine combination shows success in cells
A possible treatment and vaccine combination for COVID-19 has shown positive results in pre-clinical studies using human cells.
news
Atomic-scale details of SARS-CoV-2 Spike protein from vaccine obtained
The SARS-CoV-2 Spike protein from a COVID-19 vaccine candidate has been characterised by researchers, supporting the neutralising antibody response it elicits.
article
Coronavirus update: COVID-19 vaccine pre-clinical developments
Drug Target Review rounds up some of the latest news in COVID-19 vaccine candidate R&D.
news
Majority of T-cell targets not on COVID-19 Spike protein, study finds
Research has shown T cells taken from patients with COVID-19 target the same three to eight immunodominant epitopes - most of which are not on the Spike protein.
news
Team redesigns COVID-19 Spike protein for more stable vaccines
Researchers have modified the COVID-19 Spike protein for use in vaccines, which produces up to 10 times more protein than that of an earlier synthetic versions.